Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000241759 | SCV000302164 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000590631 | SCV000695388 | benign | not provided | 2017-03-15 | criteria provided, single submitter | clinical testing | Variant summary: The COL5A1 c.2431-25G>A variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a benign outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing while ESE finder predicts the loss of a SRp40 binding motif. However, these predictions have yet to be confirmed by functional studies. This variant was found in 16316/120916 control chromosomes (1295 homozygotes) at a frequency of 0.1349367, which is approximately 107949 times the estimated maximal expected allele frequency of a pathogenic COL5A1 variant (0.0000013), suggesting this variant is likely a benign polymorphism. In addition, one clinical diagnostic laboratory and one reputable database classified this variant as benign. Taken together, this variant is classified as benign. |
Gene |
RCV000590631 | SCV001873333 | benign | not provided | 2018-06-26 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002270100 | SCV002554160 | benign | Ehlers-Danlos syndrome, classic type, 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002270101 | SCV002554161 | benign | Fibromuscular dysplasia, multifocal | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000590631 | SCV005321054 | benign | not provided | criteria provided, single submitter | not provided |